(NASDAQ: AMPH) Amphastar Pharmaceuticals's forecast annual revenue growth rate of 3.72% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.39%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.18%.
Amphastar Pharmaceuticals's revenue in 2025 is $731,967,000.On average, 3 Wall Street analysts forecast AMPH's revenue for 2025 to be $35,168,171,804, with the lowest AMPH revenue forecast at $35,028,556,950, and the highest AMPH revenue forecast at $35,276,814,080. On average, 3 Wall Street analysts forecast AMPH's revenue for 2026 to be $37,109,914,235, with the lowest AMPH revenue forecast at $35,978,700,362, and the highest AMPH revenue forecast at $37,907,577,260.
In 2027, AMPH is forecast to generate $38,891,552,259 in revenue, with the lowest revenue forecast at $37,464,907,636 and the highest revenue forecast at $40,246,245,199.